| چکیده انگلیسی مقاله |
Introduction: TRPV1 is a non-selective cation channel with high permeability to calcium ions, and is also involved in the development of neurogenic and inflammatory pain. The increase in intracellular calcium plays a role in worsening of stroke. In the present study we investigated the effect of (AMG9810) TRPV1 receptor antagonist on stroke outcome in the permanent middle cerebral artery occlusion model in rat. Methods: In this experimental study, a total of 24 male Wistar rats weighing 250-300g were divided into 3 groups as following: control, treatment and sham. Stroke was induced by permanent middle cerebral artery occlusion method. The animals were then treated with the TRPV1 receptor antagonist Amg9810 (0.5 mg/kg, ip) and vehicle (DMSO) 3h after stroke. Infarct volume was determined by TTC staining, and sensory motor deficits were assessed by sticky and hanging tests at 1, 3 and 7 days after stroke induction, and compared. Results: One week after stroke, Amg9810 decreased the cortical infarct volume (P< 0.05). The touch time and remove time (in sticky test) was decreased in these animals (P< 0.001) but hanging test was increased (P< 0.01). Conclusion: TRPV1 receptor inhibition may decrease infarct volume and sensory-motor deficits following stroke due to permanent middle cerebral artery occlusion in rat. |
| نویسندگان مقاله |
الهام حکیمی زاده | elham hakimizadeh
dept. of physiology, physiology-pharmacology research center, rafsanjan university of medical sciences, pharmacology research center, rafsanjan university of medical sciences, rafsanjan, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی رفسنجان (Rafsanjan university of medical sciences)
علی شمسی زاده | ali shamsizadeh
dept. of physiology, physiology-pharmacology research center, rafsanjan university of medical sciences,
سازمان اصلی تایید شده: دانشگاه علوم پزشکی رفسنجان (Rafsanjan university of medical sciences)
رضا وزیری نژاد | reza vazirinejad
dept. of epidemiology, rafsanjan university of medical sciences, rafsanjan, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی رفسنجان (Rafsanjan university of medical sciences)
محمد کاظمی عرب آبادی | mohammad kazemi arababadi
dept. of immunology, immunology of infectious diseases research center, rafsanjan university of medical sciences,rafsanjan, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی رفسنجان (Rafsanjan university of medical sciences)
حسین رضازاده | hossein rezazadeh
dept. of immunology, immunology of infectious diseases research center, rafsanjan university of medical sciences,rafsanjan, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی رفسنجان (Rafsanjan university of medical sciences)
مسعود مبینی | masoud mobini
dept. of physiology, physiology-pharmacology research center, rafsanjan university of medical sciences, pharmacology research center, rafsanjan university of medical sciences, rafsanjan, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی رفسنجان (Rafsanjan university of medical sciences)
وحید احسانی | vahid ehsani
dept. of physiology, physiology-pharmacology research center, rafsanjan university of medical sciences, pharmacology research center, rafsanjan university of medical sciences, rafsanjan, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی رفسنجان (Rafsanjan university of medical sciences)
محمد الله توکلی | mohammad allahtavakoli
dept. of physiology, physiology-pharmacology research center, rafsanjan university of medical sciences, pharmacology research center, rafsanjan university of medical sciences, rafsanjan, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی رفسنجان (Rafsanjan university of medical sciences)
|